News
At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...
The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade ...
Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.
5d
TipRanks on MSNAstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...
New draft guidance from the National Institute for Health and Care Excellence suggests the NHS should move away from a one-size-fits-all approach.
6d
TipRanks on MSNAstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
The new label for Forxiga/Farxiga (dapagliflozin) comes from the DECLARE-TIMI 58 trial, and the EU is the first major market to approve the label update, ahead of the US and China where it remains ...
AstraZeneca's Farxiga (dapagliflozin) for diabetes, heart failure, and chronic kidney disease – down 68% to $178.50; Immunex's Enbrel (aflibercept) for rheumatoid arthritis, psoriasis, and ...
Researchers from Thomas Jefferson University have discovered that combining two diabetes drugs—dapagliflozin and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results